Crystal modifications of elobixibat

US9701649B2 · kind B2 · utility

Assignee

• ELOBIX AB · SE

Inventors

• Martin Bohlin · Stockholm, SE
• Erica Tjerneld · Stuvsta-Snättringe, SE
• Andreas Vestermark · Stockholm, SE
• Ingvar Ymen · Boo, SE

Key dates

• Filing date: Apr 21, 2016
• Grant date: Jul 11, 2017
• Expiry date: Apr 21, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to crystal modifications of N-{(2R)-2-[({[3,3-dibutyl-7-(methyl-thio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl]oxy}acetyl)amino]-2-phenylethanolyl}glycine (elobixibat), more specifically crystal modifications I, IV, MeOH-1, EtOH-1, 1-PrOH-1 and 2-PrOH-1. The invention also relates to a process for the preparation of these crystal modifications and to a pharmaceutical composition comprising crystal modification IV.